Navigation Links
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Date:4/10/2008

687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 42825384.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including; the conduct and timing of studies; timing of regulatory submissions; timing of regulatory review and approval; commercialization of products; market acceptance of products; dependence on strategic collaborative partners; intellectual property protection and disputes; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
5. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
9. Mercury Therapeutics Patents Filed
10. Cell Therapeutics, Inc. Announces Filing of Form 10-K
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...,Who: David Appia, French Ambassador for Internati...t in France Agency, , , , ,What: Ambassador Appia... pro-business initiatives adopted by France to fur...ndscape for innovation and development., , ,When: ...
(Date:11/24/2009)...celand,November24/PRNewswire-FirstCall/--deCODE,ge...eceivednoticefrom,theNasdaqStockMarketthattradingi...er30,2009andaForm25-NSEwillbefiledwiththe,Securiti...monstock,fromlistingonNasdaq,unlessthecompanyfiles...companyhasfiledsuchanappeal,which,willstaythesuspe...
(Date:11/24/2009)...v.24/PRNewswire-Asia/--NODPharmaceuticalsInc.annou...dthepatentapplicationfor,itsnano-particleoraldeliv...fficientapproachtoincorporatepeptidesor,proteinsin...drugs,otherwiseadministeredasinjections.NODtechnol...romoleculardrugssuchasinsulin,interferon,growthho...
(Date:11/24/2009)... The FBI recently approved the Promega Power...ating in or generating DNA records for the Nationa...ison, WI USA (PRWEB) -- The FBI recently approved ...by laboratories participating in, or generating DN...). NDIS currently contains more than seven million...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...H, N.J., Jan. 9 Schering-Plough Corporation (NYSE...resentation by Thomas P. Koestler, Ph.D., executiv...search Institute, at the 27th Annual J.P. Morgan H...an. 12, at approximately 3:30 p.m. (PST) (6:30 p.m...mpany,s R&D pipeline and select projects in de...
...RD, Pa., Jan. 9 Endo Pharmaceuticals (Nasdaq: E...t and Chief Executive Officer of Endo, will presen...l Healthcare Conference on Wednesday, January 14, ...ill be held January 12-15, 2009 in San Francisco. ...tation may be accessed on the Endo Website at www...
...N, Ireland, January 9 Azur Pharma Limited ("Azur,...usive U.S. marketing rights,for Niravam(R) (alpraz...arbidopa-levodopa orally disintegrating tablets), ...s) and Fluxid(TM) (famotidine orally,disintegratin...ms were not,disclosed. , Niravam, Parcopa and ...
Other Biology Technology:Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2
(Date:11/24/2009)...ch Institute (LRI) today named 12 new grant recipi...recognize innovative work across a broad spectrum ...ativity, novelty, and potential to drive scientifi... the complex disease of systemic lupus. , The 20...earchers across the nation and include interdiscip...
(Date:11/24/2009)... weakened and flabby arteries from collapsing have...e stents are no longer needed -- once the arteries...usly, doctors had no choice but to leave them in p...rsity,s Department of Biomedical Engineering has d...carries drugs where they,re needed, then dissolves...
(Date:11/24/2009)...NEW YORK (November 24, 2009) -- The Wildlife Conse...ealing that the last remaining population of Siber...o the rising tide of poaching and habitat loss. ,... Russian officials of what needs to be done to pro...cat. , The report was released by t...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Report shows dramatic decline in Siberian tigers 2Employment Policies Institute Launches 2410 Million Campaign Urging the Public to Rethink Health Care Reform 61198 1Employment Policies Institute Launches 2410 Million Campaign Urging the Public to Rethink Health Care Reform 61198 2Speedus Corp Names Stephen X Graham to Board of Directors 61195 1Speedus Corp Names Stephen X Graham to Board of Directors 61195 2Memphis Mayor Endorses National Bipolar Foundation 61190 1Memphis Mayor Endorses National Bipolar Foundation 61190 2
... rise in autoimmune diseases such as multiple scle...nvironmental factors could be the cause of this in...esis" in which an excessively germ-free environmen...s that a decline in infectious diseases may play a...The first study examining the relationship between...
...ysis of nicotine yield from major brand name cigar...confirmed that manufacturers have steadily increas...dependent analysis, based on data submitted to the...by the manufacturers, found that increases in smok...t each year, or about 11 percent over a seven-year...
... drugs (opioids) are commonly prescribed for short...tiveness long-term has been questioned in a review..., who also found that behaviors consistent with op... "Patients with chronic back pain commonly request...despite the concerns clinicians have with patients...
Other Biology News:Parasite infection may benefit MS patients 2Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent 2Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent 3
...the 4000 Q TRAP(TM) LC/MS/MS System, a high perfor...s spectrometer for the drug discovery, drug develo...Ion Trap (LIT) Technology from the leaders in mass...itative analysis with the proven, high sensitivity...
...d salt solution. It is routinely used as an antico...age of whole blood at refrigerator temperatures fo...ume of blood is collected into a container of this...lution is placed in a refrigerator at 2-8 C for 2 ...
Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
Chicken Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: